FDA Approves Obinutuzumab (Gazyva) for Primary Membranous Nephropathy

On November 13, 2026, the FDA approved obinutuzumab (Gazyva) to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression, the first drug approved in the US for this disease. The approval rests on the open-label phase 3 MAJESTY trial versus tacrolim

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.